Article
Biomarkers and surrogacy: relevance to chemoprevention.
IARC scientific publications - 1 Jan 2001
Kensler T W, Davidson N E, Groopman J D, Muñoz A
Abstract excerpt
Clinical cancer prevention trials that use disease as the end-point are of necessity large, lengthy and costly. While such trials will always remain the 'gold standard' for establishing efficacy, they are unwieldy and inefficient for the rapid translation of our accelerating understanding of the molecular basis of cancer into preventive strategies. The inclusion of biomarkers in the process of chemopreventive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.